Modelling the impacts of new diagnostic tools for tuberculosis in developing countries to enhance policy decisions

Health Care Management Science

Volumn 15, Issue 3, 2012, Pages 239-253

  Langley, Ivor ^a   Doulla, Basra ^b   Lin, Hsien Ho ^c   Millington, Kerry ^a   Squire, Bertie ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b Ministry of Health and Social Welfare   (Tanzania)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cost effectiveness; Developing Countries; Simulation; Transmission modelling; Tuberculosis

Indexed keywords

EID: 84864541966     PISSN: 13869620     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10729-012-9201-3     Document Type: Article

References (37)

1. World Health Organisation World TB Control (2011) http://www. who. int/tb/publications/global_report/2011/gtbr11_full. pdfhttp://www. who. int/mediacentre/factsheets/fs104/en/.
2. Stop TB Partnership (2009) The Global Plan to Stop TB 2011-2015 Progress Report 2006-2008 http://www. stoptb. org/assets/documents/global/plan/The_global_plan_progress_report1. pdf.
3. Kemp JR, Mann G, Simwaka BN, Salaniponi FM, Squire SB (2007) Can Malawi's poor afford free tuberculosis services? Patient and household costs associated with a tuberculosis diagnosis in Lilongwe. Bull World Health Organ 85(8): 580-585.
4. Liu X, Thomson R, Gong Y, Zhao F, Squire SB, Tolhurst R, Zhoa X, Yan F, Tang S (2007) How affordable are tuberculosis and treatment in rural China? Trop Med Int Health 12. doi: 10. 111/j. 1365-3156. 2007. 01953. x.
5. Squire SB, Belaye AK, Kashoti A, Salaniponi FM, Mundy CJ, Theobald S et al (2005) 'Lost' smear-positive pulmonary tuberculosis cases: where are they and why did we lose them? Int J Tuberc Lung Dis 9(1): 25-31.
6. Marais BJ, Brittle W, Painczyk K, Hesseling AC, Beyers N, Wasserman E et al (2008) Use of light-emitting diode fluorescence microscopy to detect acid-fast bacilli in sputum. Clin Infect Dis 47(2): 203-207.
7. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F et al (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363(11): 1005-1015.
8. Morgan M, Kalantri S, Flores L, Pai M (2005) A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 5: 62.
9. Ramsay A, Yassin MA, Cambanis A, Hirao S, Almotawa A, Gammo M et al (2009) Front-loading sputum microscopy services: an opportunity to optimise smear-based case detection of tuberculosis in high prevalence countries. J Trop Med 2009: 398767.
10. Small PM, Pai M (2010) Tuberculosis diagnosis - time for a game change. N Engl J Med 363(11): 1070-1071.
11. World Health Organization (2011) WHO endorses new rapid tuberculosis test. http://www. who. int/tb/laboratory/new_rapid_test/en/index. html.
12. Squire SB, Ramsay A, van den Hof S, Millington K, Langley I, Bello G, Kritski A, Detjen A, Thomson R, Cobelens F, Mann G (2011) Making innovations accessible to the poor through implementation by research. Int J Tuberc Lung Dis 15(7): 1-9. doi: 10. 5588/ijtld. 11. 0161.
13. Mann G, Squire SB, Bissell K, Eliseev P, Du Toit E, Hesseling A et al (2010) Beyond accuracy: creating a comprehensive evidence base for TB diagnostic tools. Int J Tuberc Lung Dis 14(12): 1518-1524.
14. Kapsali M, Bolt T, Bayer S, Brailsford S (2010) The simulation model as an object between boundaries, Proceedings HaCIRIC International Conference.
15. Katsaliaki K, Mustafee N (2011) Applications of simulation within the healthcare context. J Oper Res Soc 201162: 1431-1451.
16. Günal M, Pidd M (2010) Discrete event simulation for performance modelling in health care: a review of the literature. J Simul 4: 42-51.
17. Reynolds M, Vasilakis C et al (2011) Using discrete event simulation to design a more efficient hospital pharmacy for outpatients. Health Care Manag Sci 14: 223-236. doi: 10. 1007/s10729-011-9151-1.
18. Lanner Case studies. (accessed June 2011); Available from: http://www. lanner. com/en/case-studies. cfm?offset=6.
19. Anderson RM, May RM (1991) Infectious diseases of humans: dynamics and control. Oxford University Press.
20. Murray CJ, Salomon JA (1998) Modeling the impact of global tuberculosis control strategies. Proc Natl Acad Sci U S A 95(23): 13881-13886.
21. Blower SM, McLean AR, Porco TC, Small PM, Hopewell PC, Sanchez MA et al (1995) The intrinsic transmission dynamics of tuberculosis epidemics. Nat Med 1(8): 815-821.
22. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM Jr, Dye C et al (2009) Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A 106(33): 13980-13985.
23. Dowdy DW, Chaisson RE, Maartens G, Corbett EL, Dorman SE (2008) Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci U S A 105(32): 11293-11298.
24. Treatment of tuberculosis: guidelines for national programmes, WHO/CDS/TB/2003. 313.
25. Treatment of tuberculosis guidelines, Fourth Edition, World Health Organisation, WHO/HTM/TB/2009. 420.
26. FIND (2010), FIND negotiated prices for Xpert® MTB/RIF and Country list, (Accessed June 2011, http://www. finddiagnostics. org/about/whatwedo/successes/find-negotiated-prices/xpert_mtb_rif. html.
27. Hargreaves NJ, Kadzakumanja O, Whitty CJ, Salaniponi FM, Harries AD, Squire SB (2001) 'Smear-negative' pulmonary tuberculosis in a DOTS programme: poor outcomes in an area of high HIV seroprevalence. Int J Tuberc Lung Dis 5: 847-854.
28. Swai H, Mugusi F, Mbwambo K (2011) Sputum smear negative pulmonary tuberculosis: sensitivity and specificity of diagnostic algorithm. BMC Res Notes 4: 475.
29. Rapid Implementation of the Xpert MTB/RIF diagnostic test, Technical and Operational 'How-to' Practical considerations http://whqlibdoc. who. int/publications/2011/9789241501569_eng. pdf.
30. Boehme CC, Nicol M, Nabeta P, Michael JS, Gotuzzo E et al (2011) Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377. doi: 10. 1016/S0140-6736(11)60438-8.
31. WHO Guide to Cost Effectiveness Analysis, http://www. who. int/choice/publications/p_2003_generalised_cea. pdf.
32. WHO - Health statistics and health information systems - http://www. who. int/healthinfo/global_burden_disease/metrics_daly/en/.
33. WHO Global Health Observatory Data Repository - Country Statistics - United Republic of Tanzania, 2010 http://apps. who. int/ghodata/?vid=20700&theme=country.
34. Shillcutt SD, Walker DG, Goodman CA, Mills AJ (2009) Cost-effectiveness in low and middle income countries. Pharmacoeconomics 27(11): 903-917. doi: 10. 2165/10899580.
35. World Bank, World development report - Investing in Health (1993).
36. Lin HH, Langley I, Mwenda R, Doulla B, Egwaga S, Millington KA, Mann GH, Murray M, Squire SB, Cohen T (2011) A modelling framework to support the selection and implementation of new tuberculosis diagnostic tools. Int J Tuberc Lung Dis 15(8): 996-1004. doi: 10. 5588/ijtld. 11. 0062.
37. Moore DA, Shah NS (2011) Alternative methods of diagnosing drug resistance-what can they do for me? J Infect Dis 204(Suppl 4): S1110-S1119.